The invention describes novel nitrosated and/or nitrosylated
prostaglandins, and novel compositions comprising at least one nitrosated
and/or nitrosylated prostaglandin, and, optionally, at least one compound
that donates, transfers or releases nitric oxide, elevates endogenous
levels of endothelium-derived relaxing factor, stimulates endogenous
synthesis of nitric oxide or is a substrate for nitric oxide synthase,
and/or at least one vasoactive agent. The invention also provides novel
compositions comprising at least one prostaglandin and at least one
S-nitrosothiol compound, and, optionally, at least one vasoactive agent.
The prostaglandin is preferably a prostaglandin E.sub.1 compound, more
preferably alprostadil, and the S-nitrosothiol compound is preferably
S-nitrosoglutathione. The invention also provides methods for treating or
preventing sexual dysfunctions in males and females, for enhancing sexual
responses in males and females, and for treating or preventing
cerebrovascular disorders, cardiovascular disorders, benign prostatic
hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions.